Literature DB >> 12847329

Diabetes insipidus and Langerhans cell histiocytosis: a case report of reversibility with 2-chlorodeoxyadenosine.

Fabio Ottaviano1, Jonathan L Finlay.   

Abstract

Diabetes insipidus (DI) is the most common manifestation of central nervous system involvement in Langerhans cell histiocytosis (LCH). Patients with LCH involving the head and neck region are reported to have about a 40% lifetime chance of developing DI. The clinical and biochemical diagnosis of DI is sometimes supported by the absence of the posterior pituitary bright signal on magnetic resonance images. Cladribine (2-chlorodeoxyadenosine, 2-CDA) has been reported as an active drug in children and adults with relapsed or refractory LCH. The authors report the successful reversal of DI in a 3-year-old child with established LCH using 2-CDA.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12847329     DOI: 10.1097/00043426-200307000-00017

Source DB:  PubMed          Journal:  J Pediatr Hematol Oncol        ISSN: 1077-4114            Impact factor:   1.289


  9 in total

1.  Analysis of 43 cases of Langerhans cell histiocytosis (LCH)-induced central diabetes insipidus registered in the JLSG-96 and JLSG-02 studies in Japan.

Authors:  Yoko Shioda; Souichi Adachi; Shinsaku Imashuku; Kazuko Kudo; Toshihiko Imamura; Akira Morimoto
Journal:  Int J Hematol       Date:  2011-11-17       Impact factor: 2.490

2.  Spontaneous gonadotrophin deficiency recovery in an adult patient with Langerhans cell histiocytosis (LCH).

Authors:  Polyzois Makras; Dimitrios Papadogias; George Kontogeorgos; George Piaditis; Gregory A Kaltsas
Journal:  Pituitary       Date:  2005       Impact factor: 4.107

3.  Treatment of patients with hypothalamic-pituitary lesions as adult-onset Langerhans cell histiocytosis.

Authors:  Shinsaku Imashuku; Naoko Kudo; Shigehiro Kaneda; Hiroshi Kuroda; Tsuguka Shiwa; Tetsuya Hiraiwa; Atsushi Inagaki; Akira Morimoto
Journal:  Int J Hematol       Date:  2011-10-21       Impact factor: 2.490

Review 4.  Langerhans cell histiocytosis.

Authors:  Kevin Bradford Hoover; Daniel I Rosenthal; Henry Mankin
Journal:  Skeletal Radiol       Date:  2006-10-07       Impact factor: 2.128

Review 5.  Successful management of multiple-systemic Langerhans cell histiocytosis involving endocrine organs in an adult: A case report and review of literature.

Authors:  Junhui Xie; Zhen Li; Yi Tang
Journal:  Medicine (Baltimore)       Date:  2018-06       Impact factor: 1.889

6.  Second-line regimen for CNS-involved pediatric Langerhans cell histiocytosis.

Authors:  Hongyun Lian; Lei Cui; Ying Yang; Ang Wei; Hua Cheng; Na Li; Li Zhang; Honghao Ma; Xiaoxi Zhao; Tianyou Wang; Zhigang Li; Rui Zhang
Journal:  Pituitary       Date:  2021-07-24       Impact factor: 4.107

7.  Langerhans cell histiocytosis (LCH): guidelines for diagnosis, clinical work-up, and treatment for patients till the age of 18 years.

Authors:  Riccardo Haupt; Milen Minkov; Itziar Astigarraga; Eva Schäfer; Vasanta Nanduri; Rima Jubran; R Maarten Egeler; Gritta Janka; Dragan Micic; Carlos Rodriguez-Galindo; Stefaan Van Gool; Johannes Visser; Sheila Weitzman; Jean Donadieu
Journal:  Pediatr Blood Cancer       Date:  2012-10-25       Impact factor: 3.167

8.  Laryngeal Langerhans Cell Histiocytosis Presenting with Neck Mass in an Adult Woman.

Authors:  Hesam Jahandideh; Yasser Nasoori; Sara Rostami; Mahdi Safdarian
Journal:  Case Rep Otolaryngol       Date:  2016-04-05

9.  Clinical Characteristics of Pediatric Patients With Sellar and Suprasellar Lesions Who Initially Present With Central Diabetes Insipidus: A Retrospective Study of 55 Cases From a Large Pituitary Center in China.

Authors:  Xin Ji; Zihao Wang; Wenze Wang; Lu Gao; Xiaopeng Guo; Chenzhe Feng; Wei Lian; Kan Deng; Bing Xing
Journal:  Front Endocrinol (Lausanne)       Date:  2020-02-20       Impact factor: 5.555

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.